An investigation was announced for investors in NASDAQ:ELGX shares over possible breaches of fiduciary duties by certain Endologix Inc directors.
Investors who are investors in Endologix, Inc. (NASDAQ:ELGX) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm for current long term investors in NASDAQ:ELGX stocks follows a lawsuit filed recently against Endologix, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:ELGX stocks, concerns whether certain Endologix officers and directors are liable in connection with the allegations made in that lawsuit.
The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System, and that as a result, Endologix’s public statements were materially false and misleading at all relevant times.
On May 18, 2017, NASDAQ:EGLX shares closed at $4.26 per share.
Those who purchased NASDAQ:ELGX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego